CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 98 enrolled
Drug / intervention
Oxycodone Naloxone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00944697
NCT00944697Phase 2Completed

An Exploratory, Randomised, Double-blind, Single-dummy, Placebo Controlled, Parallel Group Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy

Mundipharma Research GmbH & Co KG·interventional·Posted Jul 23, 2009·Updated Aug 17, 2012

In Brief

A Phase 2 clinical trial evaluating Oxycodone Naloxone and Placebo tablets for Moderate to Severe Pain Due to Diabetic Polyneuropathy. Completed, enrolled 98 participants across 1 site.

Detailed Summary

To show superior analgesic efficacy of OXN PR in addition to a patient's current dose of pregabalin compared to pregabalin alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 23, 2009
Enrollment StartJul 1, 2009
Primary CompletionMar 1, 2010
Study CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.9 years ago

Interventions

Oxycodone Naloxonedrug

Oxycodone Naloxone tablets

Placebo tabletsdrug

Placebo Oxycodone Naloxone tablets